Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy

• Published in: Healthcare (Basel) Vol. 10; no. 10; p. 2004
• Main Authors: Gomez-Ramirez, Eli E, Ramirez-Villafaña, Melissa, Gamez-Nava, Jorge I, Cons-Molina, Fidencio, Rodriguez Jimenez, Norma A, Saldaña-Cruz, Ana M, Cardona-Muñoz, Ernesto G, Totsuka-Sutto, Sylvia E, Ponce-Guarneros, Juan M, Trujillo, Xochitl, Huerta, Miguel, Cruz-Jentoft, Alfonso J, Gonzalez-Lopez, Laura
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.10.2022; MDPI
• Subjects: Body composition; Chronic illnesses; Combination therapy; Complications and side effects; csDMARDs; Demographic aspects; Disease; Health aspects; Infections; Muscle diseases; muscle wasting; Musculoskeletal system; myopenia; Patients; Remission (Medicine); Rheumatoid arthritis; Risk factors; Sarcopenia; therapy failure; Variables; Wasting syndrome; Women; Womens health; Mexico; myopenia; therapy failure; rheumatoid arthritis; muscle wasting; csDMARDs
• ISSN: 2227-9032; 2227-9032
• DOI: 10.3390/healthcare10102004

Background: Muscle wasting, also known as myopenia, is frequent in rheumatoid arthritis (RA). To date, it is still unknown if the failure of pharmacologic therapies increases the risk of myopenia in RA. Objective: To identify if treatment failure with conventional synthetic DMARDs (csDMARDs) constitutes an independent risk factor of muscle wasting in women with RA. Methods: This was a cross-sectional study. We included 277 women with RA. Assessments in RA patients included: clinical, epidemiological, and therapeutic variables. The skeletal muscle index (SMI) was estimated by DXA, and myopenia was diagnosed if they had an SMI < 5.45 kg/m2. Multivariable logistic regression models identified risk factors of myopenia. Results: Muscle wasting was observed in 28.2% of patients with RA. The risk factors of myopenia in RA were menopausal (OR: 4.45, 95% CI: 1.86 to 10.64) and failure of combined therapy with csDMARDs (OR: 2.42, 95% CI: 1.15 to 5.07). The increased body mass index was protective (OR:0.81, 95% CI: 0.75 to 0.87). Conclusions: Around one of four patients with RA presented muscle wasting. Muscle wasting is related to treatment failure of combined csDMARDs; other factors influencing the presence of muscle wasting is being postmenopausal, whereas, the body mass index was a protective factor.